Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
RADNOR, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced financial results for the quarter ending March 31, 2023, and provided a corporate update.
- ET –
RADNOR, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced financial results for the quarter ending March 31, 2023, and provided a corporate update. - We expect this trial to readout topline data in the first half of 2024,” stated Jon Congleton, Chief Executive Officer of Mineralys Therapeutics.
- General and Administrative (G&A) expenses were $2.6 million for the quarter ended March 31, 2023, compared to $0.8 million for the quarter ended March 31, 2022.
- Net loss was $12.6 million for the quarter ended March 31, 2023, compared to $7.6 million for the quarter ended March 31, 2022.